Blood · 2022 · 31 citations · 37 references
Life SciencesImmunologyPharmacologyCell SignalingImmunoregulationTransplant ImmunologyHematopoietic Stem Cell Transplant PharmacotherapyImmune ReconstitutionInnate Immunity In TransplantationStem Cell Signaling PathwaysTransplant ImmunotherapyAllogeneic Stem Cell InfusionAllogeneic Stem Cell TherapyMetabolic Interaction NetworksPost-transplant Relapse ProphylaxisRelapse After Transplantation
Administration of azithromycin after allogeneic hematopoietic stem cell transplantation for hematologic malignancies has been associated with relapse in a randomized phase 3 controlled clinical trial. Studying 240 samples from patients randomized in this trial is a unique opportunity to better understand the mechanisms underlying relapse, the first cause of mortality after transplantation. We used multi-omics on patients' samples to decipher immune alterations associated with azithromycin intake and post-transplantation relapsed malignancies. Azithromycin was associated with a network of altered energy metabolism pathways and immune subsets, including T cells biased toward immunomodulatory and exhausted profiles. In vitro, azithromycin exposure inhibited T-cell cytotoxicity against tumor cells and impaired T-cell metabolism through glycolysis inhibition, down-regulation of mitochondrial genes, and up-regulation of immunomodulatory genes, notably SOCS1. These results highlight that azithromycin directly affects immune cells that favor relapse, which raises caution about long-term use of azithromycin treatment in patients at high risk of malignancies. The ALLOZITHRO trial was registered at www.clinicaltrials.gov as #NCT01959100.
37
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Vijay Shankaran, Hiroaki Ikeda, Allen T. Bruce et al. · Nature · 2001 · 2.8K citations
Life Sciences, Immunology, Oncology +12
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink, Sangeetha M. Reddy, Jianjun Gao et al. · Nature · 2020 · 2.7K citations · Full text
Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo
Henning Walczak, Robert E. Miller, K. Ariail et al. · Nature Medicine · 1999 · 2.5K citations
TOX is a critical regulator of tumour-specific T cell differentiation
Andrew Scott, Friederike Dündar, Paul Zumbo et al. · Nature · 2019 · 1.1K citations · Full text
Life Sciences, Immunology, Oncology +14